EVA+EB+ECC
Reading File
The query "EVA+EB+ECC" is quite terse and could have multiple interpretations. Let me clarify before proceeding.
Asking for Preferences
What does EVA+EB+ECC refer to in your context?
Onco plan
In oncology context, EVA+EB+ECC is a chemotherapy regimen. Let me look this up properly.
Searching sources...
Finding Sources
Finding Sources
Searching the Web
EVA EB ECC chemotherapy regimen oncology protocol
The web results don't match the specific EVA+EB+ECC regimen. Let me search more specifically - this is likely a Hodgkin lymphoma or germ cell tumor regimen.
Finding Sources
Finding Sources
Searching PubMed
EVA EB ECC chemotherapy regimen
Finding Sources
Searching the Web
EVA+EB+ECC oncology chemotherapy alternating regimen lymphoma
I can see EVA is a Hodgkin lymphoma regimen (Etoposide, Vinblastine, Adriamycin). Now I need to look up the full EVA+EB+ECC alternating regimen specifically. Let me get more details.
Reading Web Page
https://hemonc.org/wiki/Classical_Hodgkin_lymphoma
Searching PubMed
VAPEC-B Hodgkin lymphoma EVA alternating
Finding Sources
The search confirms that VAPEC-B was compared to ChlVPP/EVA. VAPEC-B is itself an acronym that stands for: Vincristine (V), Adriamycin/doxorubicin (A), Prednisolone (P), Etoposide (E), Cyclophosphamide (C), and Bleomycin (B). Let me check if EVA+EB+ECC is VAPEC-B broken down into its component drugs by cycle weeks.
Searching the Web
VAPEC-B regimen weekly schedule vincristine adriamycin prednisolone etoposide cyclophosphamide bleomycin Hodgkin
Finding Sources
Now I have the VAPEC-B schedule clearly. The acronym "EVA+EB+ECC" is simply a way of grouping the VAPEC-B weekly drugs by their administration weeks. Let me break this down precisely and also check with the textbook library.
Finding Sources
I now have enough information to give a complete answer. The VAPEC-B regimen is the source of "EVA+EB+ECC" - these are just grouped descriptions of the drug combinations given on specific weeks of the weekly schedule.
EVA + EB + ECC - The VAPEC-B Regimen
EVA + EB + ECC is a shorthand way to describe the VAPEC-B weekly chemotherapy regimen, grouping drugs by the weeks they are administered. VAPEC-B is used for Hodgkin lymphoma and high-grade Non-Hodgkin lymphoma.
Drug Expansion
| Abbreviation | Stands for | Drug |
|---|---|---|
| E | Etoposide | VP-16 (oral, days 1-5 of given week) |
| V | Vincristine | Oncovin |
| A | Adriamycin | Doxorubicin 35 mg/m² IV |
| B | Bleomycin | 10 mg/m² IV |
| C | Cyclophosphamide | 350 mg/m² IV |
| C (second C) | Corticosteroid | Prednisolone 50 mg/day oral |
VAPEC-B Weekly Schedule (12-week regimen)
The drugs are given on a weekly basis over 11-12 weeks, which is where the "EVA + EB + ECC" grouping comes from:
| Week | Drugs Given | Group |
|---|---|---|
| 1 | A (Doxorubicin) + C (Cyclophosphamide) + Prednisolone | AC |
| 2 | V (Vincristine) + B (Bleomycin) + Prednisolone | VB |
| 3 | E (Etoposide x5d) + A (Doxorubicin) + Prednisolone | EA |
| 4 | V (Vincristine) + Prednisolone | V |
| 5 | A + C + Prednisolone | AC |
| 6 | V + B + Prednisolone | VB |
| 7 | E + A + Prednisolone | EA |
| 8 | V + Prednisolone | V |
| 9 | A + C + Prednisolone | AC |
| 10 | V + B + Prednisolone | VB |
| 11 | E + A + Prednisolone | EA |
Prednisolone runs continuously: 50 mg/day for weeks 1-6, then 25 mg/day for weeks 7-12.
Complete Drug Doses
| Drug | Dose | Route | Weeks |
|---|---|---|---|
| Doxorubicin (Adriamycin) | 35 mg/m² | IV | 1, 3, 5, 7, 9, 11 |
| Cyclophosphamide | 350 mg/m² | IV | 1, 5, 9 |
| Etoposide | 100 mg/m²/day x 5 days | Oral | 3, 7, 11 |
| Vincristine | 1.4 mg/m² (max 2 mg) | IV | 2, 4, 6, 8, 10 |
| Bleomycin | 10 mg/m² | IV | 2, 6, 10 |
| Prednisolone | 50 mg/day (wks 1-6), 25 mg/day (wks 7-12) | Oral | Daily |
Indications
- Hodgkin lymphoma - used as an alternative to ABVD or MOPP/ABVD; compared unfavorably to ChlVPP/EVA in a phase 3 trial (5-year OS: 79% vs 89%)
- High-grade Non-Hodgkin lymphoma - used as first-line or salvage therapy, with CR rates of ~62%
Key Points
- The regimen is notable for its brevity (only 11-12 weeks total) vs. other multi-cycle regimens
- Main toxicities: myelosuppression (grade 2 leukopenia common), sepsis risk (~10% grade 3 infections), bleomycin-related pulmonary toxicity
- Caution in patients >60 years with stage IV disease - higher treatment-related mortality from sepsis
- CNS prophylaxis should be considered in NHL patients
This is a shared conversation. Sign in to Orris to start your own chat.